安徽宏宇五洲医疗器械股份有限公司 信息披露暂缓与豁免管理制度 安徽宏宇五洲医疗器械股份有限公司 信息披露暂缓与豁免管理制度 安徽宏宇五洲医疗器械股份有限公司董事会 二〇二五年十月 信息披露暂缓与豁免管理制度 安徽宏宇五洲医疗器械股份有限公司 第一章 总则 第一条 为规范安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"） 的信息披露暂缓与豁免行为，加强信息披露监管，保护投资者的合法权益，根据 《中华人民共和国保守国家秘密法》《中华人民共和国证券法》《上市公司信息披 露管理办法》《上市公司信息披露暂缓与豁免管理规定》等法律、行政法规、部 门规章、规范性文件及公司章程的规定，结合公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会（以下简称中国证监会）和深圳证 券交易所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实施 内幕交易、操纵市场等违法行为。 第二章 信息披露暂缓与豁免的范围 第四条 公司和其 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-033 安徽宏宇五洲医疗器械股份有限公司 关于修订公司章程及修订、制定部分治理制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 为全面贯彻落实最新法律法规要求，进一步完善公司治理结构，规范公司运 作，根据《中华人民共和国公司法》（以下简称"《公司法》"）《关于新<公 司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》等相关法律、 法规及规范性文件的规定，安徽宏宇五洲医疗器械股份有限公司（以下简称"公 司"）于 2025 年 10 月 22 日召开第三届董事会第十次会议，审议通过了《关于 修订〈公司章程〉的议案》《关于修订、制定公司部分治理制度的议案》，公司 将不再设置监事会和监事，由董事会审计委员会行使原监事会的相关职权。现将 具体情况公告如下： 一、《公司章程》的修订情况 1、删除"监事""监事会"相关描述，部分描述由"审计委员会"代替； 2、将"股东大会"修改为"股东会"； 3、依据《公司法》《上市公司章程指引》等规定进行的其他修订。 | 原章程内容 | 修订后的章程内容 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-034 安徽宏宇五洲医疗器械股份有限公司 关于召开 2025 年度第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会 7、出席对象： （1）截至 2025 年 11 月 7 日下午深圳证券交易所收市时，在中国证券登记结算有限 责任公司深圳分公司登记在册的公司全体股东，上述公司全体股东均有权出席本次股东会， 并可以书面形式委托代理人出席和参加表决，该股东代理人不必是公司股东； （2）公司董事、监事及高级管理人员； （3）公司聘请的律师及其他相关人员； （4）根据相关法规应当出席股东会的其他人员。 3、会议召开的合法、合规性：经公司第三届董事会第十次会议审议通过，决议召开 公司 2025 年第一次临时股东会。本次股东会召集程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定，召集人资格及程序合法有效。 4、会议时间： （1）现场会议时间：2025 年 11 月 13 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-031 监事会认为：董事会编制的《2025 年第三季度报告》的程序符合法律法规 和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司的实际情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届监事会第 九次会议于 2025 年 10 月 22 日以现场结合通讯方式在公司会议室召开，会议于 2025 年 10 月 15 日以书面和通讯方式通知全体监事。本次会议应出席监事 3 名， 实际出席监事 3 名。 本次会议由公司监事会主席吴国英先生主持，公司全体董事及高级管理人员 列席了本次会议。会议的召开符合《公司法》等法律法规和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过《关于<2025 年第三季度报告>的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 三、备查 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-030 安徽宏宇五洲医疗器械股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届董事会第 十次会议于 2025 年 10 月 22 日以现场结合通讯方式在公司会议室召开，会议于 2025 年 10 月 15 日以书面和通讯方式通知全体董事。本次会议应出席董事 7 名， 实际出席董事 7 名。 本次会议由公司董事长黄凡先生主持，公司监事及高级管理人员列席了会议。 会议的召开符合《公司法》等法律法规、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于<2025 年第三季度报告>的议案》 2、审议通过《关于修订<公司章程>的议案》 根据中国证券监督管理委员会发布的《关于新<公司法>配套制度规则实施相 关过渡期安排》《上市公司章程指引》等规范性文件的规定，结合公司实际情况， 公司将不再设置监事会或者监事，由董事会审计委员会行使《公司法》规定的监 事会的职权 ...

Financial Performance - The company's revenue for Q3 2025 was CNY 128,498,738.52, a decrease of 1.51% compared to the same period last year[7]. - Net profit attributable to shareholders decreased by 36.39% to CNY 7,994,259.30, while the year-to-date net profit decreased by 46.09% to CNY 18,509,389.16[7]. - Basic and diluted earnings per share both fell by 36.36% to CNY 0.1176[7]. - Total operating revenue for the current period reached ¥345,417,868.30, a slight increase from ¥342,595,211.54 in the previous period, representing a growth of approximately 0.84%[24]. - Operating profit for the current period was ¥23,479,459.16, down from ¥40,874,703.36 in the previous period, indicating a decline of approximately 42.4%[24]. - The total profit for the current period is ¥18,509,389.16, a decrease of 46.0% compared to ¥34,335,329.36 in the previous period[25]. - The net profit attributable to the parent company's shareholders is ¥18,509,389.16, reflecting a 46.0% decline from ¥34,335,329.36 year-over-year[25]. - The basic and diluted earnings per share for the current period are both ¥0.2722, down from ¥0.5049 in the previous period, representing a 46.0% decrease[25]. - The company’s total comprehensive income for the current period is ¥18,509,389.16, down 46.0% from ¥34,335,329.36 in the previous period[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 867,498,308.29, a decrease of 0.59% from the end of the previous year[7]. - Total assets as of September 30, 2025, amounted to ¥867,498,308.29, slightly down from ¥872,667,220.25 at the beginning of the period, a decrease of approximately 0.6%[20]. - Total liabilities decreased to ¥106,863,577.34 from ¥110,170,830.92, reflecting a decline of about 3%[20]. - Non-current assets totaled ¥306,227,243.18, down from ¥324,852,711.62, a decrease of approximately 5.8%[20]. - Inventory levels decreased to ¥39,640,778.12 from ¥44,779,230.07, a reduction of about 11.5%[19]. Cash Flow - Cash flow from operating activities for the current period is ¥69,076,293.49, compared to ¥73,855,724.26 in the previous period, indicating a decline of 6.5%[27]. - Cash inflow from investment activities is ¥853,948,042.86, an increase from ¥628,890,104.22 in the previous period, marking a growth of 35.7%[27]. - Cash outflow from investment activities is ¥931,432,771.04, up from ¥778,483,765.35 in the previous period, reflecting an increase of 19.6%[27]. - The net cash flow from investment activities is -¥77,484,728.18, an improvement from -¥149,593,661.13 in the previous period[27]. - The cash and cash equivalents at the end of the period amount to ¥125,582,982.32, down from ¥167,991,874.58 in the previous period, a decrease of 25.2%[28]. - The company reported a decrease in cash flow from financing activities, with a net cash flow of -¥20,571,047.54 compared to -¥27,381,218.60 in the previous period, showing an improvement of 25.5%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,986[13]. - The largest shareholder, Huang Fan, holds 24.16% of the shares, totaling 16,429,650 shares[13]. - The second-largest shareholder, Xiang Bingyi, owns 20.25% of the shares, amounting to 13,770,000 shares[13]. - The total number of shares with limited sale conditions at the beginning of the period was 49,587,900, with 49,572,000 shares released from restrictions during the period[15]. - The company’s controlling shareholder and actual controller, Huang Fan, will change after the expiration of the joint action agreement on July 5, 2025[16]. - The company has a total of 27,829,387 shares that remain under lock-up conditions at the end of the reporting period[15]. - The number of shares held by the top ten shareholders accounts for a significant portion of the total shares, with Huang Fan and Xiang Bingyi being the most prominent[13]. - The company has no preferred shareholders or changes in preferred shareholder status reported[14]. - There are no shareholders participating in margin financing or securities lending activities[14]. - The company plans to release 49,572,000 shares for public trading after the lock-up period ends[16]. Expenses - Research and development expenses decreased by 32.01% to CNY 5,727,947.61, primarily due to a reduction in R&D personnel[11]. - Sales expenses increased by 50.15% to CNY 11,799,884.10, mainly due to higher compensation for sales staff[11]. Investment Income - Investment income rose by 110.87% to CNY 3,671,037.32, attributed to increased returns from financial products[11]. - The company reported a net investment income of ¥3,671,037.32, compared to ¥1,740,896.22 in the previous period, indicating an increase of approximately 110.5%[24]. - Cash received from investment redemption increased by 35.80% to CNY 851,457,122.75, reflecting higher amounts redeemed from financial products[11]. - Deferred income increased by 35.54% to CNY 18,054,679.60, mainly due to an increase in government subsidies related to assets[12]. - The company received government subsidies amounting to CNY 354,134.11 during the reporting period, contributing to its non-operating income[8].

Market Overview - The medical device sector increased by 0.72% on October 15, with TuoJing Life leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Top Performers - TuoJing Life (300642) closed at 25.85, up 10.38% with a trading volume of 294,900 shares and a transaction value of 756 million [1] - JiMin Health (603222) closed at 10.97, up 10.03% with a trading volume of 353,400 shares [1] - MaiLanDe (688273) closed at 43.90, up 9.75% with a trading volume of 47,500 shares [1] - KeFu Medical (301087) closed at 43.10, up 7.86% with a trading volume of 72,700 shares [1] - Rejing Bio (688068) closed at 170.79, up 6.96% with a trading volume of 34,700 shares [1] Underperformers - JinHao Medical (920925) closed at 34.05, down 3.81% with a trading volume of 15,400 shares [2] - DaBo Medical (002901) closed at 55.52, down 2.94% with a trading volume of 29,400 shares [2] - HuaDa ZhiZao (688114) closed at 68.57, down 2.93% with a trading volume of 52,400 shares [2] Capital Flow - The medical device sector saw a net inflow of 500 million in main funds, while retail investors experienced a net outflow of 214 million [2][3] - Major stocks like SaiNuo Medical (688108) had a net inflow of 129 million from main funds, while JiMin Health (603222) saw a net outflow of 471 million from retail investors [3]

Group 1 - The core viewpoint of the news is that Wuzhou Medical has seen a stock price increase of 5.37%, reaching 49.45 CNY per share, with a total market capitalization of 3.363 billion CNY [1] - Wuzhou Medical, established on April 15, 2011, specializes in the research, production, and sales of disposable sterile infusion medical devices, primarily using an ODM and integrated supply model to meet the procurement needs of foreign medical device brands [1] - The main revenue composition of Wuzhou Medical includes: 41.29% from syringes, 25.51% from medical puncture needles, 20.92% from infusion and blood transfusion devices, and 12.28% from other products [1] Group 2 - From the perspective of the top ten circulating shareholders, the Noan Fund holds a significant position, with its Noan Multi-Strategy Mixed A fund increasing its holdings by 181,600 shares in the second quarter, now holding 327,900 shares, which is 1.78% of the circulating shares [2] - The Noan Multi-Strategy Mixed A fund has achieved a year-to-date return of 61.5%, ranking 305 out of 8161 in its category, and an annual return of 85.65%, ranking 98 out of 8015 [2]

Core Viewpoint - Wuzhou Medical (301234) experienced a stock price increase of 6.13% on October 13, 2025, closing at 46.22 yuan, with a trading volume of 32,400 hands and a total transaction amount of 147 million yuan [1] Group 1: Stock Performance and Trading Data - On October 13, 2025, the main funds had a net outflow of 20.95 million yuan, accounting for 14.25% of the total transaction amount, while retail investors had a net inflow of 17.15 million yuan, representing 11.67% of the total [1] - Over the past five days, the stock's closing prices and changes were as follows: - October 13: 46.22 yuan (+6.13%) - October 10: 43.55 yuan (-2.73%) - October 9: 44.77 yuan (+2.92%) - September 30: 43.50 yuan (+0.35%) - September 29: 43.35 yuan (+3.17%) [2] Group 2: Financing and Margin Trading - On October 13, 2025, the financing balance was 95.73 million yuan, with a net financing purchase of 5.77 million yuan [3] - The financing data for the past five days showed fluctuations in financing balance and net purchases, with the highest net purchase recorded on October 13 [3] Group 3: Company Financials and Industry Comparison - Wuzhou Medical reported a main revenue of 217 million yuan for the first half of 2025, a year-on-year increase of 2.26%, but a net profit of 10.52 million yuan, a decrease of 51.69% [5] - Key financial metrics for Wuzhou Medical compared to the medical device industry average include: - Total Market Value: 3.159 billion yuan vs. 11.912 billion yuan - Net Assets: 753 million yuan vs. 3.889 billion yuan - Net Profit: 10.5151 million yuan vs. 149 million yuan - PE Ratio: 150.19 vs. 66.32 - Gross Margin: 14.33% vs. 51.85% [5]

Core Viewpoint - The company, Wuzhou Medical, is experiencing a decline in stock price while benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise in the medical device sector [1][2][3]. Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other medical supplies [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022. Its main revenue sources include syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. Financial Performance - For the first half of 2025, Wuzhou Medical reported a revenue of 217 million yuan, representing a year-on-year growth of 2.26%, while the net profit attributable to the parent company was 10.52 million yuan, a decrease of 51.69% year-on-year [7]. - As of August 20, 2023, the company had 6,048 shareholders, a decrease of 16.64% from the previous period, with an average of 11,243 circulating shares per person, an increase of 19.96% [7]. Market Position and Recognition - Wuzhou Medical's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3]. Stock Performance - On October 10, the stock price of Wuzhou Medical fell by 2.73%, with a trading volume of 64.05 million yuan and a turnover rate of 2.15%, bringing the total market capitalization to 2.961 billion yuan [1].